Search Results - "Sydes, Matthew"

Practical methods for incorporating summary time-to-event data into meta-analysis by Tierney, Jayne F, Stewart, Lesley A, Ghersi, Davina, Burdett, Sarah, Sydes, Matthew R

“…In systematic reviews and meta-analyses, time-to-event outcomes are most appropriately analysed using hazard ratios (HRs). In the absence of individual patient…”
Get full text

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data by Vale, Claire L, Fisher, David, Kneebone, Andrew, Parker, Christopher, Pearse, Maria, Richaud, Pierre, Sargos, Paul, Sydes, Matthew R, Brawley, Christopher, Brihoum, Meryem, Brown, Chris, Chabaud, Sylvie, Cook, Adrian, Forcat, Silvia, Fraser-Browne, Carol, Latorzeff, Igor, Parmar, Mahesh K B, Tierney, Jayne F

“…It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally…”
Get full text

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data by Vale, Claire L, Dr, Burdett, Sarah, MSc, Rydzewska, Larysa H M, BSc, Albiges, Laurence, MD, Clarke, Noel W, Prof, Fisher, David, MSc, Fizazi, Karim, Prof, Gravis, Gwenaelle, MD, James, Nicholas D, Prof, Mason, Malcolm D, Prof, Parmar, Mahesh K B, Prof, Sweeney, Christopher J, MBBS, Sydes, Matthew R, CStat, Tombal, Bertrand, Prof, Tierney, Jayne F, PhD

“…Summary Background Results from large randomised controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensitive prostate…”
Get full text

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer by Xie, Wanling, Regan, Meredith M, Buyse, Marc, Halabi, Susan, Kantoff, Philip W, Sartor, Oliver, Soule, Howard, Clarke, Noel W, Collette, Laurence, Dignam, James J, Fizazi, Karim, Paruleker, Wendy R, Sandler, Howard M, Sydes, Matthew R, Tombal, Bertrand, Williams, Scott G, Sweeney, Christopher J

“…Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer decreases the number of deaths from this disease. Surrogates for overall…”
Get full text

Adaptive designs in clinical trials: why use them, and how to run and report them by Pallmann, Philip, Bedding, Alun W, Choodari-Oskooei, Babak, Dimairo, Munyaradzi, Flight, Laura, Hampson, Lisa V, Holmes, Jane, Mander, Adrian P, Odondi, Lang'o, Sydes, Matthew R, Villar, Sofía S, Wason, James M S, Weir, Christopher J, Wheeler, Graham M, Yap, Christina, Jaki, Thomas

“…Adaptive designs can make clinical trials more flexible by utilising results accumulating in the trial to modify the trial's course in accordance with…”
Get full text

When to randomize patients in a randomized controlled trial? by Lensen, Sarah, Sydes, Matthew R., Polyakov, Alex, Wilkinson, Jack

“…The timing of randomization should be considered carefully in the context of each trial because it has implications for the particular research question…”
Get full text

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis by Burdett, Sarah, Boevé, Liselotte M., Ingleby, Fiona C., Fisher, David J., Rydzewska, Larysa H., Vale, Claire L., van Andel, George, Clarke, Noel W., Hulshof, Maarten C., James, Nicholas D., Parker, Christopher C., Parmar, Mahesh K., Sweeney, Christopher J., Sydes, Matthew R., Tombal, Bertrand, Verhagen, Paul C., Tierney, Jayne F.

“…Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). To systematically review trials of prostate…”
Get full text

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial by Dearnaley, David P, Prof, Jovic, Gordana, PhD, Syndikus, Isabel, FRCR, Khoo, Vincent, FRCR, Cowan, Richard A, FRCR, Graham, John D, FRCR, Aird, Edwin G, PhD, Bottomley, David, FRCR, Huddart, Robert A, FRCR, Jose, Chakiath C, FRANZCR, Matthews, John H L, FRANZCR, Millar, Jeremy L, FRANZCR, Murphy, Claire, BSc, Russell, J Martin, FRCR, Scrase, Christopher D, FRCR, Parmar, Mahesh K B, Prof, Sydes, Matthew R, MSc

“…Summary Background The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with…”
Get full text

More multiarm randomised trials of superiority are needed by Parmar, Mahesh K B, Carpenter, James, Sydes, Matthew R

“…Compellingly, increasing the number of research arms increases the probability within one trial of reliably showing that at least one new treatment is superior…”
Get full text

Medicines and Healthcare products Regulatory Agency's "Consultation on proposals for legislative changes for clinical trials": a response from the Trials Methodology Research Partnership Adaptive Designs Working Group, with a focus on data sharing by Law, Martin, Couturier, Dominique-Laurent, Choodari-Oskooei, Babak, Crout, Phillip, Gamble, Carrol, Jacko, Peter, Pallmann, Philip, Pilling, Mark, Robertson, David S, Robling, Michael, Sydes, Matthew R, Villar, Sofía S, Wason, James, Wheeler, Graham, Williamson, S Faye, Yap, Christina, Jaki, Thomas

“…In the UK, the Medicines and Healthcare products Regulatory Agency consulted on proposals "to improve and strengthen the UK clinical trials legislation to help…”
Get full text

Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform by Gillessen, Silke, Gilson, Clare, James, Nick, Adler, Amanda, Sydes, Matthew R, Clarke, Noel

“…Take Home Message Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate…”
Get full text

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial by Warde, Padraig, Dr, Mason, Malcolm, MB, Ding, Keyue, PhD, Kirkbride, Peter, MB, Brundage, Michael, MD, Cowan, Richard, MB, Gospodarowicz, Mary, MD, Sanders, Karen, BSc, Kostashuk, Edmund, MD, Swanson, Greg, MD, Barber, Jim, MB, Hiltz, Andrea, MSc, Parmar, Mahesh KB, PhD, Sathya, Jinka, MB, Anderson, John, MB, Hayter, Charles, MD, Hetherington, John, MB, Sydes, Matthew R, CStat, Parulekar, Wendy, MD

“…Summary Background Whether the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer managed with androgen…”
Get full text

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial by Parker, Christopher C, Clarke, Noel W, Cook, Adrian D, Kynaston, Howard G, Petersen, Peter Meidahl, Catton, Charles, Cross, William, Logue, John, Parulekar, Wendy, Payne, Heather, Persad, Rajendra, Pickering, Holly, Saad, Fred, Anderson, Juliette, Bahl, Amit, Bottomley, David, Brasso, Klaus, Chahal, Rohit, Cooke, Peter W, Eddy, Ben, Gibbs, Stephanie, Goh, Chee, Gujral, Sandeep, Heath, Catherine, Henderson, Alastair, Jaganathan, Ramasamy, Jakobsen, Henrik, James, Nicholas D, Kanaga Sundaram, Subramanian, Lees, Kathryn, Lester, Jason, Lindberg, Henriette, Money-Kyrle, Julian, Morris, Stephen, O'Sullivan, Joe, Ostler, Peter, Owen, Lisa, Patel, Prashant, Pope, Alvan, Popert, Richard, Raman, Rakesh, Røder, Martin Andreas, Sayers, Ian, Simms, Matthew, Wilson, Jim, Zarkar, Anjali, Parmar, Mahesh K B, Sydes, Matthew R

“…The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant…”
Get full text

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer by Hoyle, Alex P., Ali, Adnan, James, Nicholas D., Cook, Adrian, Parker, Christopher C., de Bono, Johann S., Attard, Gerhardt, Chowdhury, Simon, Cross, William R., Dearnaley, David P., Brawley, Christopher D., Gilson, Clare, Ingleby, Fiona, Gillessen, Silke, Aebersold, Daniel M., Jones, Rob J., Matheson, David, Millman, Robin, Mason, Malcolm D., Ritchie, Alastair W.S., Russell, Martin, Douis, Hassan, Parmar, Mahesh K.B., Sydes, Matthew R., Clarke, Noel W.

“…Abiraterone acetate received licencing for use in only “high-risk” metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings…”
Get full text

Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? by Sylvester, Richard J, Oosterlinck, Willem, Holmang, Sten, Sydes, Matthew R, Birtle, Alison, Gudjonsson, Sigurdur, De Nunzio, Cosimo, Okamura, Kikuo, Kaasinen, Eero, Solsona, Eduardo, Ali-El-Dein, Bedeir, Tatar, Can Ali, Inman, Brant A, N’Dow, James, Oddens, Jorg R, Babjuk, Marek

“…Abstract Context The European Association of Urology non–muscle-invasive bladder cancer (NMIBC) guidelines recommend that all low- and intermediate-risk…”
Get full text

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer by Mason, Malcolm D, Parulekar, Wendy R, Sydes, Matthew R, Brundage, Michael, Kirkbride, Peter, Gospodarowicz, Mary, Cowan, Richard, Kostashuk, Edmund C, Anderson, John, Swanson, Gregory, Parmar, Mahesh K B, Hayter, Charles, Jovic, Gordana, Hiltz, Andrea, Hetherington, John, Sathya, Jinka, Barber, James B P, McKenzie, Michael, El-Sharkawi, Salah, Souhami, Luis, Hardman, P D John, Chen, Bingshu E, Warde, Padraig

“…We have previously reported that radiotherapy (RT) added to androgen-deprivation therapy (ADT) improves survival in men with locally advanced prostate cancer…”
Get full text

A strategy to reduce the carbon footprint of clinical trials by Adshead, Fiona, Al-Shahi Salman, Rustam, Aumonier, Simon, Collins, Michael, Hood, Kerry, McNamara, Carolyn, Moore, Keith, Smith, Richard, Sydes, Matthew R, Williamson, Paula R

“…Almost 14 years ago the Sustainable Clinical Trials Group concluded that “clinical trials contribute substantially to greenhouse gas emissions”, notably…”
Get full text

Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy by Kerns, Sarah L, Fachal, Laura, Dorling, Leila, Barnett, Gillian C, Baran, Andrea, Peterson, Derick R, Hollenberg, Michelle, Hao, Ke, Narzo, Antonio Di, Ahsen, Mehmet Eren, Pandey, Gaurav, Bentzen, Søren M, Janelsins, Michelle, Elliott, Rebecca M, Pharoah, Paul D P, Burnet, Neil G, Dearnaley, David P, Gulliford, Sarah L, Hall, Emma, Sydes, Matthew R, Aguado-Barrera, Miguel E, Gómez-Caamaño, Antonio, Carballo, Ana M, Peleteiro, Paula, Lobato-Busto, Ramón, Stock, Richard, Stone, Nelson N, Ostrer, Harry, Usmani, Nawaid, Singhal, Sandeep, Tsuji, Hiroshi, Imai, Takashi, Saito, Shiro, Eeles, Rosalind, DeRuyck, Kim, Parliament, Matthew, Dunning, Alison M, Vega, Ana, Rosenstein, Barry S, West, Catharine M L

“…Abstract Background A total of 10%–20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic…”
Get full text

The Lancet Commission on prostate cancer: planning for the surge in cases by James, Nicholas D, Tannock, Ian, N'Dow, James, Feng, Felix, Gillessen, Silke, Ali, Syed Adnan, Trujillo, Blanca, Al-Lazikani, Bissan, Attard, Gerhardt, Bray, Freddie, Compérat, Eva, Eeles, Ros, Fatiregun, Omolara, Grist, Emily, Halabi, Susan, Haran, Áine, Herchenhorn, Daniel, Hofman, Michael S, Jalloh, Mohamed, Loeb, Stacy, MacNair, Archie, Mahal, Brandon, Mendes, Larissa, Moghul, Masood, Moore, Caroline, Morgans, Alicia, Morris, Michael, Murphy, Declan, Murthy, Vedang, Nguyen, Paul L, Padhani, Anwar, Parker, Charles, Rush, Hannah, Sculpher, Mark, Soule, Howard, Sydes, Matthew R, Tilki, Derya, Tunariu, Nina, Villanti, Paul, Xie, Li-Ping

“…For the Commission, we established four working groups, each of which examined a different aspect of prostate cancer: epidemiology and future projected trends…”
Get full text

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial by Bielack, Stefan S, Smeland, Sigbjørn, Whelan, Jeremy S, Marina, Neyssa, Jovic, Gordana, Hook, Jane M, Krailo, Mark D, Gebhardt, Mark, Pápai, Zsuzsanna, Meyer, James, Nadel, Helen, Randall, R Lor, Deffenbaugh, Claudia, Nagarajan, Rajaram, Brennan, Bernadette, Letson, G Douglas, Teot, Lisa A, Goorin, Allen, Baumhoer, Daniel, Kager, Leo, Werner, Mathias, Lau, Ching C, Sundby Hall, Kirsten, Gelderblom, Hans, Meyers, Paul, Gorlick, Richard, Windhager, Reinhard, Helmke, Knut, Eriksson, Mikael, Hoogerbrugge, Peter M, Schomberg, Paula, Tunn, Per-Ulf, Kühne, Thomas, Jürgens, Heribert, van den Berg, Henk, Böhling, Tom, Picton, Susan, Renard, Marleen, Reichardt, Peter, Gerss, Joachim, Butterfass-Bahloul, Trude, Morris, Carol, Hogendoorn, Pancras C W, Seddon, Beatrice, Calaminus, Gabriele, Michelagnoli, Maria, Dhooge, Catharina, Sydes, Matthew R, Bernstein, Mark

“…EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose…”
Get full text